Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)
|
By IntellAsia: Resources
on 7/22/2021
Intas Pharmaceuticals Ltd continues to pledge their commitment to increasing access to high quality medicines by entering into an exclusive license agreement AHMEDABAD, India, July 22, 2021 /PRNewswire/ -- Intas Pharm...
Full "IntellAsia: Resources" article
|
|